Introduction

Knee osteoarthritis is a widespread condition that causes ongoing pain and restricts movement for millions of people. Finding treatments that provide lasting relief is an ongoing challenge. Various injections are often used, including the well-known corticosteroids and hyaluronic acid, alongside newer options like Arthrosamid—a groundbreaking hydrogel treatment. This article aims to explain how Arthrosamid differs from traditional knee injections, offering clear information to help patients and healthcare professionals make informed choices.

The Landscape of Knee Injections: Key Options for Osteoarthritis

There are three main types of injections that doctors typically use to help manage knee osteoarthritis symptoms. First are corticosteroid injections. These work by calming inflammation inside the joint, often providing fast pain relief within days. However, their effects tend to be short-lived—usually only lasting a few weeks. Steroids are usually reserved for sudden flare-ups. Second, hyaluronic acid (HA) injections help by lubricating and cushioning the joint. They top up the joint’s natural fluid, making movement easier and easing pain. HA injections typically last longer than steroids—often several months—and are commonly prescribed for moderate osteoarthritis. More recently, hydrogel injections like Arthrosamid have emerged. Unlike steroids or HA, these treatments create a lasting physical cushioning inside the joint. This innovative approach supports joint function over a longer period and may help improve outcomes. The development of Arthrosamid reflects the growing need for treatments that go beyond short-term pain relief to truly protect and support the knee joint.

Arthrosamid Hydrogel: A Novel Approach and How It Works

Arthrosamid is based on a soft, biocompatible polyacrylamide hydrogel, which is injected directly into the knee. It works quite differently from traditional injections. Once inside, the hydrogel forms a semi-solid gel that cushions the joint, spreading out the forces placed on worn cartilage and surrounding tissues. This mechanical cushioning contrasts with steroids, which chemically reduce inflammation, and hyaluronic acid, which mainly improves lubrication but gradually breaks down and disappears over time. In simple terms, Arthrosamid works by physically supporting the joint space for an extended period, providing continuous relief from mechanical stress. This can help reduce pain and improve mobility for longer than some other treatments. Importantly, recent laboratory studies have shown reassuring safety results: “2.5 iPAAG had no statistically significant effects on cell survival, non-apoptotic and apoptotic cell death, or the neurite network area,” confirming that this hydrogel does not damage nerve cells in vitro. You might think of Arthrosamid as a soft gel pad nestled between the joint surfaces, cushioning impact and smoothing movement in a way fluid injections cannot match.

Comparative Effectiveness: Arthrosamid vs. Hyaluronic Acid and Steroid Injections

Many patients and clinicians ask how Arthrosamid stacks up against more familiar treatments like steroids and hyaluronic acid. Steroid injections usually deliver the fastest pain relief, often within a few days, by quickly reducing inflammation. Hyaluronic acid and Arthrosamid take longer to work, as they rely on mechanical support rather than chemical effects. When it comes to how long relief lasts, Arthrosamid has been shown to provide longer-lasting benefits—effects have been observed for up to a year or more. As one systematic review noted, “statistically significant data was identified in two studies at both 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post injection.” Functionally, Arthrosamid appears to help patients maintain better knee mobility compared to those receiving steroids or hyaluronic acid. One recent study found that “iPAAG outperformed Steroid at 6 months... but not HA.” However, it is worth noting that differences between treatments become less clear beyond six months. The same research points out that, “although overall differences at 12 months were significant... iPAAG offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited.” Side effects are generally mild for all three injection types. Importantly, the same review confirmed that “injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported.” Also, specific safety studies highlight that the hydrogel “demonstrates no apparent in vitro neurotoxic or cytotoxic effects.” Understanding these nuances helps patients and doctors make thoughtful decisions, with Arthrosamid’s unique cushioning mechanism offering an appealing option for sustained joint support.

Patient Experience and Long-Term Benefits: What Makes Arthrosamid Stand Out

Beyond clinical data, hearing about real patient experiences is vital. Many people treated with Arthrosamid report longer-lasting pain relief and better mobility. This sustained improvement often means fewer repeat injections and can postpone the need for surgery. For instance, one patient with chronic knee pain reported significant improvements in daily activities and was able to delay considering knee replacement surgery after receiving Arthrosamid. These stories highlight the potential of Arthrosamid not only to ease symptoms but to enhance quality of life. As one systematic review succinctly put it, “this PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years.” At the same time, experts remind us that “it may be a complementary option in individualised osteoarthritis management,” and that “further prospective studies are needed to define its optimal use.” By weighing these factors, patients and clinicians can make personalised choices that best suit individual needs.

Conclusion

Arthrosamid offers a distinct approach to knee osteoarthritis treatment through its durable cushioning effect within the joint. This innovative hydrogel provides longer-lasting pain relief and helps improve function, setting it apart from traditional steroid and hyaluronic acid injections. Armed with this knowledge, patients and healthcare professionals can have confident, informed discussions to select the most appropriate treatment. As research continues to evolve, therapies like Arthrosamid promise a hopeful future for those living with knee osteoarthritis.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(6). https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina-Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430